Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Neurocrine Biosciences (NBIX) unveiled a groundbreaking study on August 12, demonstrating INGREZZA's ability to alleviate the daily struggles of tardive dyskinesia (TD) beyond what traditional rating scales measure. The KINECT-PRO Phase 4 trial included 59 patients who took INGREZZA for 24 weeks, with 52 completing the study. Among the 45 included in the efficacy analysis, 58% achieved symptomatic remission on clinician-rated movement severity.

Notably, even patients with mild TD symptoms experienced significant improvement. This effect was observed early, with patients exceeding the clinically meaningful threshold for movement severity by week 4 and reporting a better quality of life by week 8. The drug's safety profile remained consistent with previous data. This clinical success coincides with a robust business expansion, with Neurocrine's revenue increasing 39% year-over-year to $959 million in Q2.

INGREZZA sales grew 15% to $716 million, with new prescriptions surpassing expectations. Management raised its full-year INGREZZA guidance to $2.825 billion to $2.875 billion, highlighting the drug's growing importance in the company's portfolio. The acquisition of Soleno Therapeutics for $2.9 billion in May contributed to a significant cash outflow, reducing Neurocrine's cash and marketable securities from $2.5 billion to $482 million by June.

To counterbalance these financial challenges, the company issued a $1.0 billion revolving credit facility. Operating expenses are also on the rise, with R&D costs increasing to $327 million and SG&A expenses to $440 million. Despite diversifying its pipeline with CRENESSITY and VYKAT XR, INGREZZA still accounts for three-quarters of Neurocrine's quarterly revenue.

The stock is trading at a forward P/E of 14.88, indicating a cautious market sentiment amid the company's aggressive growth strategy and reliance on INGREZZA for future success.